Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors

NCT05906862 is registered in ClinicalTrials.gov with Multitude Therapeutics (Australia) Pty Ltd as lead sponsor.

NCT NCT05906862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05906862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors
Lead sponsor
Multitude Therapeutics (Australia) Pty Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
November 6, 2023
Completion date
December 30, 2026
Enrollment
54 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor